The institutional story around @injective continues to take shape. After the recent Canary Staked INJ ETF development, there’s now a fresh update to the 21Shares Injective ETF. 21Shares has amended its existing S-1 filing, originally submitted in October 2025, adding more details to its proposed spot ethereum:0xe28b3b32b6c345a34ff64674606124dd5aceca30 ETF. ⇢ Staking : Target allocation of 40 to 60% of the fund’s ethereum:0xe28b3b32b6c345a34ff64674606124dd5aceca30 holdings to staking, adjustable according to liquidity requirements. ⇢ Proposed Listing: The ETF is proposed to trade on Nasdaq under the ticker TINJ. ⇢ Pricing Benchmark: The fund will use the FTSE Injective Index as its reference benchmark for ethereum:0xe28b3b32b6c345a34ff64674606124dd5aceca30 pricing. ⇢ Fund Administration: BNY Mellon is designated to serve as the fund’s administrator, transfer agent, and cash custodian. And if the ethereum:0xe28b3b32b6c345a34ff64674606124dd5aceca30 ETF gets approved? 👀 ➜ Broader institutional access to INJ ➜ Increased regulatory credibility for the asset ➜ Strengthened longterm network security through staking participation ethereum:0xe28b3b32b6c345a34ff64674606124dd5aceca30 is getting closer to ETF 👀
Eagle.inj🥷🏻 PRMRShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.